Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | Myeloma updates: TAK-079, quadruplet regimens, MRD & bone disease

Noopur Raje • 7 Dec 2019
ASH 2019
Multiple Myeloma Antibodies Carfilzomib Denosumab Elotuzumab Mezagitamab Pomalidomide Zoledronic acid
GRIFFIN MASTER

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, highlights the key updates in the multiple myeloma (MM) field from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Prof. Raje specifically discusses data for the anti-CD38 monoclonal antibody mezagitamab (TAK-079), four-drug combination regimens, as well as MRD testing to assess deep responses in MM and bone disease.

More from Noopur Raje

Investigating molecular characteristics of patients with myeloma and EMD: findings & implications 1:42
Investigating molecular characteristics of patients with myeloma and EMD: findings & implications
Noopur Raje • 16 May 2025
The potential of using PD-1 inhibition to resensitize CAR-T refractory myeloma 1:54
The potential of using PD-1 inhibition to resensitize CAR-T refractory myeloma
Noopur Raje • 16 May 2025
Which next-generation CAR constructs hold promise for treating myeloma? 3:22
Which next-generation CAR constructs hold promise for treating myeloma?
Noopur Raje • 16 May 2025
The impact of CHIP on clinical outcomes in patients with myeloma treated with BCMA CAR-T 1:14
The impact of CHIP on clinical outcomes in patients with myeloma treated with BCMA CAR-T
Noopur Raje • 16 May 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals